TABLE 1.

CD81 binding of mutant E1E2 clones does not predict their infectivity in the HCVpp assaya

CD81 bindingMutants for which HCVpp infectivity was:
PositiveNegative
PositiveN417A, S419A, P484A, P491A, P525A, T526A, N532A, D533A, T534A, V538A, N540A, P544A, P545AQ412, L413A, I414A, N415A, T416A, G418A, H421A, I422A, N423A, R483A, Y485A, W487A, H488A, Y489A, G523A, R543A, G547A, W549A, F550A
NegativeW420A, Y527A, W529A, G530A, D535A
  • a A panel of alanine replacement E1E2 mutants were generated, expressed in HEK 293T cells, and tested for their ability to bind to MAb H53 and GST-CD81 LEL, as well as their ability to confer infectivity in the HCVpp assay. Binding and infectivity were expressed as percentages of that observed for wild-type H77c E1E2 protein. CD81 binding and HCVpp infectivity were normalized relative to the amount of H53-reactive E2 protein. CD81 binding and HCVpp infectivity levels that were at least 10% of that observed for wild-type H77 E1E2 were considered positive.